Search Within

Miguel-Angel Perales

Formats
  1. Meeting Abstract (498)
  2. Journal Article (362)
  3. Review (29)
  4. Research Letter (18)
  5. Guidelines (12)
  6. Book Section (10)
  7. Editorial (6)
  8. Correspondence (5)
  9. Book Whole (1)
  10. Miscellaneous (1)
Groups
  1. Bone Marrow Transplant (942)
  2. Center for Hematologic Malignancies (942)
  3. Department of Medicine (942)
  4. Hematologic Malignancies, Division of (942)
  5. Survivorship Research (474)
  6. CTCR Scholars (411)

More Groups

People
  1. Sergio Giralt (428)
  2. Sean Devlin (302)
  3. Ann Jakubowski (247)
  4. Esperanza Papadopoulos (237)
  5. Gunjan Shah (204)
  6. Molly Maloy (196)

More People

Years
  1. 2025 (30)
  2. 2024 (76)
  3. 2023 (101)
  4. 2022 (95)
  5. 2021 (68)
  6. 2020 (93)

More Years

Publications
  1. Blood (264)
  2. Biology of Blood and Marrow Transplantation (220)
  3. Bone Marrow Transplantation (86)
  4. Transplantation and Cellular Therapy (68)
  5. Blood Advances (46)
  6. Journal of Clinical Oncology (32)

More Publications

Publishers
  1. American Society of Hematology (312)
  2. Elsevier Inc. (302)
  3. Nature Publishing Group (112)
  4. American Society of Clinical Oncology (32)
  5. Oxford University Press (18)
  6. John Wiley & Sons (17)

More Publishers

Results (942)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Safety, tolerability, PK/PD and preliminary efficacy of NKTR-255, a novel IL-15 receptor agonist, in patients with relapsed/refractory hematologic malignancies
    Meeting Abstract

    Shah, N.; Tan, A.; Budde, E.; Hofmeister, C. C.; Cowan, A. J.; Perales, M. A.; Choi, T.; Saeed, H.; Chavez, J. C.; Ye, J. C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The incidence and impact of clostridioides difficile infection (CDI) on outcomes after allogeneic hematopoietic cell transplant (alloHCT) - a CIBMTR study
    Meeting Abstract

    Ramanathan, M.; Savani, B. B.; He, N. Y.; Kim, S.; Chen, M.; Chemaly, R.; Dandoy, C. E.; Perales, M. A.; Riches, M. L.; Ustun, C.
    Blood (2021)

    Fulltext@MSK | Save
  • A multicenter analysis of outcomes, toxicities, and patterns of use with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas
    Meeting Abstract

    Riedell, P. A.; Brower, J.; Nastoupil, L.; Perales, M. A.; Maziarz, R. T.; McGuirk, J. P.; Bachanova, V.; Hwang, W. T.; Schuster, S. J.; Bishop, M. R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of allogeneic hematopoietic cell transplantation (HCT) as consolidation following CD19 chimeric antigen receptor (CAR) T cell therapy for treatment of relapsed acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Park, J. H.; Nikiforow, S.; Kim, S.; Hu, Z. H.; Moskop, A.; Ahmed, S.; Abid, M. B.; Badar, T.; Bredeson, C.; Brown, V.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim results of a pilot, prospective, randomized, double-blinded, vehicle- and comparator-controlled trial on safety and efficacy of a topical inhibitor of janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non- sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease
    Meeting Abstract

    Markova, A.; Pan, A.; Dusza, S.; Chowdhury, A.; Kukoyi, O.; Perales, M. A.; Lacouture, M.; Prockop, S.; Ponce, D. M.
    Blood (2021)

    Fulltext@MSK | Save
  • Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of large B-cell lymphoma (LBCL): Impact of age and specific organ dysfunction
    Meeting Abstract

    Locke, F. L.; Jacobson, C.; Ma, L.; Dong, H.; Hu, Z. H.; Siddiqi, T.; Ahmed, S.; Ghobad, A.; Miklos, D. B.; Lin, Y.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Primary analysis of ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma
    Meeting Abstract

    Locke, F. L.; Miklos, D. B.; Jacobson, C.; Perales, M. A.; Kersten, M. J.; Oluwole, O. O.; Ghobadi, A.; Rapoport, A. P.; McGuirk, J. P.; Pagel, J. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Real-world efficacy and safety outcomes for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin's lymphoma (aBNHL) treated with commercial tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry
    Meeting Abstract

    Landsburg, D. J.; Frigault, M. J.; Hu, Z. H.; Jaglowski, S.; Locke, F. L.; Ho, C.; Perales, M. A.; Jacobson, C.; Hill, B. T.; Foley, S. R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save